Chronic lymphocytic leukaemia Australasian consensus practice statement.
CLL
consensus
diagnosis
management
Journal
Internal medicine journal
ISSN: 1445-5994
Titre abrégé: Intern Med J
Pays: Australia
ID NLM: 101092952
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
received:
30
11
2022
accepted:
30
07
2023
medline:
26
9
2023
pubmed:
25
9
2023
entrez:
24
9
2023
Statut:
ppublish
Résumé
Chronic lymphocytic leukaemia (CLL) is the most common haematological malignancy in Australia and New Zealand (ANZ). Considerable changes to diagnostic and management algorithms have occurred within the last decade. The availability of next-generation sequencing and measurable residual disease assessment by flow cytometry allow for advanced prognostication and response assessments. Novel therapies, including inhibitors of Bruton's tyrosine kinase (BTKi) and B-cell lymphoma 2 (BCL2) inhibitors, have transformed the treatment landscape for both treatment-naïve and relapsed/refractory disease, particularly for patients with high-risk genetic aberrations. Recommendations regarding appropriate supportive management continue to evolve, and special considerations are required for patients with CLL with respect to the global SARS-CoV-2 pandemic. The unique funding and treatment environments in Australasia highlight the need for specific local guidance with respect to the investigation and management of CLL. This consensus practice statement was developed by a broadly representative group of ANZ experts in CLL with endorsement by peak haematology bodies, with a view to providing this standardised guidance.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1678-1691Informations de copyright
© 2023 The Authors. Internal Medicine Journal published by John Wiley & Sons Australia, Ltd on behalf of Royal Australasian College of Physicians.
Références
Chater AM, Shorter GW, Swanson V, Kamal A, Epton T, Arden MA et al. Template for Rapid Iterative Consensus of Experts (TRICE). Int J Environ Res Public Health 2021; 18: 10255.
National Health and Medical Research Council. NHMRC Levels of Evidence and Grades for Recommendations for Guideline Developers. [Internet]. National Health and Medical Research Council; 2009. Available from URL: https://www.nhmrc.gov.au/_files_nhmrc/file/guidelines/developers/nhmrc_levels_grades_evidence_120423.pdf
Australian Institute of Health and Welfare (AIHW). Australian Cancer Incidence and Mortality (ACIM) Books: Chronic Lymphocytic Leukaemia [Internet]. Canberra: AIHW; 2021. Available from URL: http://www.aihw.gov.au/acim-books
Catovsky D, Richards S, Fooks J, Hamblin TJ. CLL trials in the United Kingdom the Medical Research Council CLL trials 1, 2 and 3. Leuk Lymphoma 1991; 5: 105-111.
Dighiero G, Maloum K, Desablens B, Cazin B, Navarro M, Leblay R et al. Chlorambucil in indolent chronic lymphocytic leukemia. N Engl J Med 1998; 338: 1506-1514.
Herling CD, Cymbalista F, Groß-Ophoff-Müller C, Bahlo J, Robrecht S, Langerbeins P et al. Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial. Leukemia 2020; 34: 2038-2050.
Langerbeins P, Zhang C, Robrecht S, Cramer P, Fürstenau M, Al-Sawaf O et al. The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia. Blood 2022; 139: 177-187.
Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood 2018; 131: 2745-2760.
Swerdlow SH, Campo E, Harris NL, Jaffe ES. World health organization classification of tumours of haematopoietic and lymphoid tissues. Revised 4th edn. IARC, Lyon; 2017.
Wierda WG, Byrd JC, Abramson JS, Bilgrami SF, Bociek G, Brander D et al. Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 4.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw 2020; 18: 185-217.
Rawstron AC, Kreuzer KA, Soosapilla A, Spacek M, Stehlikova O, Gambell P et al. Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: an European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project. Cytometry B Clin Cytom 2018; 94: 121-128.
Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E et al. The 5th edition of the World Health Organization classification of Haematolymphoid Tumours: lymphoid neoplasms. Leukemia 2022; 36: 1720-1748.
Tang C, Shen Y, Soosapilla A, Mulligan SP. Monoclonal B-cell lymphocytosis - a review of diagnostic criteria, biology, natural history, and clinical management. Leuk Lymphoma 2022; 29: 1-12.
Svensson T, Kättström M, Hammarlund Y, Roth D, Andersson PO, Svensson M et al. Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia A randomized study by the Swedish CLL group. Vaccine 2018; 36: 3701-3707.
Schuh AH, Parry-Jones N, Appleby N, Bloor A, Dearden CE, Fegan C et al. Guideline for the treatment of chronic lymphocytic leukaemia. Br J Haematol 2018; 182: 344-359.
McCaughan G, Di Ciaccio P, Ananda-Rajah M, Gilroy N, MacIntyre R, Teh B et al. COVID-19 vaccination in haematology patients: an Australian and New Zealand consensus position statement. Intern Med J 2021; 51: 763-768.
Dagnew AF, Ilhan O, Lee WS, Woszczyk D, Kwak JY, Bowcock S et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis. Lancet Infect Dis 2019; 19: 988-1000.
Crombie J, Davids MS. IGHV mutational status testing in chronic lymphocytic leukemia. Am J Hematol 2017; 92: 1393-1397.
Döhner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910-1916.
Gunn SR, Mohammed MS, Gorre ME, Cotter PD, Kim J, Bahler DW et al. Whole-genome scanning by array comparative genomic hybridization as a clinical tool for risk assessment in chronic lymphocytic leukemia. J Mol Diagn 2008; 10: 442-451.
Chun K, Wenger GD, Chaubey A, Dash DP, Kanagal-Shamanna R, Kantarci S et al. Assessing copy number aberrations and copy-neutral loss-of-heterozygosity across the genome as best practice: an evidence-based review from the Cancer Genomics Consortium (CGC) working group for chronic lymphocytic leukemia. Cancer Genet 2018; 228-229: 236-250.
Zalcberg I, D'Andrea MG, Monteiro L, Pimenta G, Xisto B. Multidisciplinary diagnostics of chronic lymphocytic leukemia: European Research Initiative on CLL - ERIC recommendations. Hematol Transfus Cell Ther 2020; 42: 269-274.
Abruzzo LV, Herling CD, Calin GA, Oakes C, Barron LL, Banks HE et al. Trisomy 12 chronic lymphocytic leukemia expresses a unique set of activated and targetable pathways. Haematologica 2018; 103: 2069-2078.
Campo E, Cymbalista F, Ghia P, Jäger U, Pospisilova S, Rosenquist R et al. TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics. Haematologica 2018; 103: 1956-1968.
Leeksma AC, Baliakas P, Moysiadis T, Puiggros A, Plevova K, van der Kevie-Kersemaekers AM et al. Genomic arrays identify high-risk chronic lymphocytic leukemia with genomic complexity: a multi-center study. Haematologica 2020; 106: 87-97.
Baliakas P, Jeromin S, Iskas M, Puiggros A, Plevova K, Nguyen-Khac F et al. Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact. Blood 2019; 133: 1205-1216.
Parmelee PA, Thuras PD, Katz IR, Lawton MP. Validation of the cumulative illness rating scale in a geriatric residential population. J Am Geriatr Soc 1995; 43: 130-137.
Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial. Lancet 2020; 395: 1278-1291.
Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med 2018; 379: 2517-2528.
Shanafelt TD, Wang XV, Hanson CA, Paietta EM, O'Brien S, Barrientos J et al. Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial. Blood 2022; 140: 112-120.
Fischer K, Al-Sawaf O, Bahlo J, Fink AM, Tandon M, Dixon M et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med 2019; 380: 2225-2236.
Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 2014; 370: 1101-1110.
Eichhorst B, Fink A-M, Bahlo J, Busch R, Kovacs G, Maurer C et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol 2016; 4846: 845-942.
Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med 2015; 373: 2425-2437.
Moreno C, Greil R, Demirkan F, Tedeschi A, Anz B, Larratt L et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2019; 20: 43-56.
Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W et al. Long-term results of alliance A041202 show continued advantage of Ibrutinib-based regimens compared with Bendamustine plus Rituximab (BR) chemoimmunotherapy. Blood 2021; 138: 639.
Tam CS, Brown JR, Kahl BS, Ghia P, Giannopoulos K, Jurczak W et al. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. Lancet Oncol 2022; 23: 1031-1043.
Tam CS, Giannopoulos K, Jurczak W, Šimkovič M, Shadman M, Österborg A et al. SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine + rituximab (BR) in patients with treatment-naïve (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Blood 2021; 138: 396.
Burger JA, Sivina M, Jain N, Kim E, Kadia T, Estrov Z et al. Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood 2019; 133: 1011-1019.
Kater AP, Carolyn O, Carol M, George F, Talha M, Mark-David L et al. Fixed-duration Ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities. NEJM Evid 2022; 1: EVIDoa2200006.
Mauro FR, Reda G, Arena V, Trentin L, Coscia M, Sportoletti P et al. Efficacy and safety of front-line venetoclax and rituximab (VenR) for the treatment of Young patients with chronic lymphocytic leukemia and an unfavorable biologic profile. Preliminary results of the Gimema study ‘Veritas’. Blood 2020; 136: 47-49.
Flinn IW, Hillmen P, Montillo M, Nagy Z, Illés Á, Etienne G et al. The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. Blood 2018; 132: 2446-2455.
Fischer K, Al-Sawaf O, Fink AM, Dixon M, Bahlo J, Warburton S et al. Venetoclax and obinutuzumab in chronic lymphocytic leukemia. Blood 2017; 129: 2702-2705.
Al-Sawaf O, Zhang C, Lu T, Liao MZ, Panchal A, Robrecht S et al. Minimal residual disease dynamics after venetoclax-obinutuzumab treatment: extended off-treatment follow-up from the randomized CLL14 study. J Clin Oncol 2021; 39: 4049-4060.
Hallek M, Fischer K, Fingerle-Rowson G, Fink A, Busch R, Mayer J et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010; 376: 1164-1174.
Fischer K, Bahlo J, Fink AM, Goede V, Herling CD, Cramer P et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood 2016; 127: 208-215.
Thompson PA, Tam CS, O'Brien SM, Wierda WG, Stingo F, Plunkett W et al. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood 2016; 127: 303-309.
Kutsch N, Bahlo J, Robrecht S, Franklin J, Zhang C, Maurer C et al. Long term follow-up data and health-related quality of life in frontline therapy of fit patients treated with FCR versus BR (CLL10 trial of the GCLLSG). HemaSphere 2020; 4: e336.
Hillmen P, Pitchford A, Bloor A, Broom A, Young M, Kennedy B et al. Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2023; 24: 535-552.
Eichhorst B, Niemann CU, Kater AP, Fürstenau M, von Tresckow J, Zhang C et al. First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia. N Engl J Med 2023; 388: 1739-1754.
Hillmen P, Pitchford A, Bloor A, Broom A, Young M, Kennedy B et al. Ibrutinib plus rituximab is superior to FCR in previously untreated CLL: results of the phase III NCRI FLAIR trial. Blood 2021; 138: 642.
Eichhorst B, Niemann C, Kater A. Time-limited venetoclax-obinutuzumab +/- ibrutinib is superior chemoimmunotherapy in frontline chronic lymphocytic leukaemia (CLL): PFS co-primary endpoint of the randomised phase 3 GAIA/CLL13 trial. 2022 EHA Congress; 2022 Jun 9; Vienna, Austria.
Tam CS, Allan JN, Siddiqi T, Kipps TJ, Jacobs R, Opat S et al. Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort. Blood 2022; 139: 3278-3289.
Allan JN, Siddiqi T, Kipps TJ, Kuss BJ, Badoux XC, Barrientos JC et al. Treatment outcomes after undetectable MRD with first-line Ibrutinib (Ibr) plus venetoclax (Ven): fixed duration treatment (placebo) versus continued Ibr with up to 5 years median follow-up in the CAPTIVATE study. Blood 2022; 140: 224-227.
Allan JN, Shanafelt T, Wiestner A, Moreno C, O'Brien SM, Braggio E et al. Long-term efficacy of first-line Ibrutinib treatment for chronic lymphocytic leukemia (CLL) with 4 years of follow-up in patients with TP53 aberrations (del(17p) or TP53 mutation): a pooled analysis from 4 clinical trials. Blood 2020; 136: 23-24.
Ahn IE, Tian X, Wiestner A. Ibrutinib for chronic lymphocytic leukemia with TP53 alterations. N Engl J Med 2020; 383: 498-500.
Moreno C, Greil R, Demirkan F, Tedeschi A, Anz B, Larratt L et al. First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial. Haematologica 2022; 107: 2108-2120.
Tam CS, Robak T, Ghia P, Kahl BS, Walker P, Janowski W et al. Zanubrutinib monotherapy for patients with treatment-naïve chronic lymphocytic leukemia and 17p deletion. Haematologica 2020; 106: 2354-2363.
Anderson MA, Tam C, Lew TE, Juneja S, Juneja M, Westerman D et al. Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax. Blood 2017; 129: 3362-3370.
Stilgenbauer S, Eichhorst B, Schetelig J, Hillmen P, Seymour JF, Coutre S et al. Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase II pivotal trial. J Clin Oncol 2018; 36: 1973-1980.
Tausch E, Schneider C, Robrecht S, Zhang C, Dolnik A, Bloehdorn J et al. Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax. Blood 2020; 135: 2402-2412.
Eichhorst B, Robak T, Montserrat E, Ghia P, Niemann CU, Kater AP et al. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2021; 32: 23-33.
Chanan-Khan A, Cramer P, Demirkan F, Fraser G, Silva RS, Grosicki S et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol 2016; 17: 200-211.
Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D'Rozario J, Assouline S et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med 2018; 378: 1107-1120.
Zelenetz AD, Barrientos JC, Brown JR, Coiffier B, Delgado J, Egyed M et al. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol 2017; 18: 297-311.
Ghia P, Pluta A, Wach M, Lysak D, Kozak T, Simkovic M et al. ASCEND: phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 2020; 38: 2849-2861.
Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum K et al. Ibrutinib treatment for first-line and relapsed/refractory chronic lymphocytic leukemia: final analysis of the pivotal phase Ib/II PCYC-1102 study. Clin Cancer Res Off J Am Assoc Cancer Res 2020; 26: 3918-3927.
Munir T, Brown JR, O'Brien S, Barrientos JC, Barr PM, Reddy NM et al. Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol 2019; 94: 1353-1363.
Jurczak W, Pluta A, Wach M, Lysak D, Kozak T, Šimkovič M et al. Three-year follow-up of the ascend trial: acalabrutinib vs rituximab plus idelalisib or bendamustine in relapsed/refractory chronic lymphocytic leukemia. Blood 2021; 138: 393.
Byrd JC, Hillmen P, Ghia P, Kater AP, Chanan-Khan A, Furman RR et al. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial. J Clin Oncol 2021; 39: 3441-3452.
Hillmen P, Eichhorst B, Brown JR, Lamanna N, 'Brien SM, Tam CS et al. Zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: interim analysis of a randomized phase III J Clin Oncol 2023; 41: 1035-1045.
Brown JR, Eichhorst B, Hillmen P, Jurczak W, Kaźmierczak M, Lamanna N et al. Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med 2023; 388: 319-332.
Coutre SE, Byrd JC, Hillmen P, Barrientos JC, Barr PM, Devereux S et al. Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood Adv 2019; 3: 1799-1807.
Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013; 369: 32-42.
Chiron D, Di Liberto M, Martin P, Huang X, Sharman J, Blecua P et al. Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma. Cancer Discov 2014; 4: 1022-1035.
Woyach JA, Ruppert AS, Guinn D, Lehman A, Blachly JS, Lozanski A et al. BTKC481S-mediated resistance to Ibrutinib in chronic lymphocytic leukemia. J Clin Oncol 2017; 35: 1437-1443.
Brandhuber B, Gomez E, Smith S, Eary T, Spencer S, Rothenberg SM et al. LOXO-305, a next generation reversible BTK inhibitor, for overcoming acquired resistance to irreversible BTK inhibitors. Clin Lymphoma Myeloma Leuk 2018; 18: S216.
Mato AR, Pagel JM, Coombs CC, Shah NN, Lamanna N, Munir T et al. Pirtobrutinib, a next generation, highly selective, non-covalent BTK inhibitor in previously treated CLL/SLL: updated results from the phase 1/2 BRUIN study. Blood 2021; 138: 391.
Mato AR, Hill BT, Lamanna N, Barr PM, Ujjani CS, Brander DM et al. Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients. Ann Oncol 2017; 28: 1050-1056.
Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 2014; 370: 997-1007.
Lunning M, Vose J, Nastoupil L, Fowler N, Burger JA, Wierda WG et al. Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2019; 134: 1811-1820.
Davids MS, Kuss BJ, Hillmen P, Montillo M, Moreno C, Essell J et al. Efficacy and safety of duvelisib following disease progression on ofatumumab in patients with relapsed/refractory CLL or SLL in the DUO crossover extension study. Clin Cancer Res 2020; 26: 2096-2103.
Davids MS, Kim HT, Nicotra A, Savell A, Francoeur K, Hellman JM et al. Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study. Lancet Haematol 2019; 6: e38-e47.
Mato AR, Roeker LE, Jacobs R, Hill BT, Lamanna N, Brander D et al. Assessment of the efficacy of therapies following venetoclax discontinuation in CLL reveals BTK inhibition as an effective strategy. Clin Cancer Res 2020; 26: 3589-3596.
Roeker LE, Dreger P, Brown JR, Lahoud OB, Eyre TA, Brander DM et al. Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents. Blood Adv 2020; 4: 3977-3989.
Lin VS, Lew TE, Handunnetti SM, Blombery P, Nguyen T, Westerman DA et al. BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax. Blood 2020; 135: 2266-2270.
Lew TE, Tam CS, Seymour JF. How I treat chronic lymphocytic leukemia after venetoclax. Blood 2021; 138: 361-369.
Thompson MC, Mato AR. Treatment of relapsed chronic lymphocytic leukemia after venetoclax. Hematol Am Soc Hematol Educ Program 2020; 2020: 18-23.
Seymour JF, Kipps TJ, Eichhorst BF, D'Rozario J, Owen CJ, Assouline S et al. Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab. Blood 2022; 140: 839-850.
Lew TE, Lin VS, Cliff ER, Blombery P, Thompson ER, Handunnetti SM et al. Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition. Blood Adv 2021; 5: 4054-4058.
Rotbain EC, Niemann CU, Rostgaard K, da Cunha-Bang C, Hjalgrim H, Frederiksen H. Mapping comorbidity in chronic lymphocytic leukemia: impact of individual comorbidities on treatment, mortality, and causes of death. Leukemia 2021; 35: 2570-2580.
Tadmor T, Welslau M, Hus I. A review of the infection pathogenesis and prophylaxis recommendations in patients with chronic lymphocytic leukemia. Expert Rev Hematol 2018; 11: 57-70.
Shen Y, Freeman JA, Holland J, Solterbeck A, Naidu K, Soosapilla A et al. COVID-19 vaccine failure in chronic lymphocytic leukaemia and monoclonal B-lymphocytosis; humoural and cellular immunity. Br J Haematol 2022; 197: 41-51.
Shen Y, Freeman JA, Holland J, Naidu K, Solterbeck A, Van Bilsen N et al. Multiple COVID-19 vaccine doses in CLL and MBL improve immune responses with progressive and high seroconversion. Blood 2022; 140: 2709-2721.
Parikh SA, Leis JF, Chaffee KG, Call TG, Hanson CA, Ding W et al. Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: natural history, clinical correlates, and outcomes. Cancer 2015; 121: 2883-2891.
Raanani P, Gafter-Gvili A, Paul M, Ben-Bassat I, Leibovici L, Shpilberg O. Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis. Leuk Lymphoma 2009; 50: 764-772.
National Blood Authority. Criteria for the Clinical Use of Intravenous Immunoglobulin in Australia, Second edn. Canberra: National Blood Authority; 2012.
Chai KL, Wong JWK, Weinkove R, Keegan A, Crispin PJ, Stanworth SJ et al. Interventions to reduce infections in patients with hematological malignancies: a systematic review and meta-analysis. Blood Adv 2023; 7: 20-31.
Keegan A, Dennington PM, Dhondy N, Mulligan SP. Immunoglobulin replacement therapy in chronic lymphocytic leukaemia patients with hypogammaglobulinaemia and infection. Eur J Haematol 2022; 108: 460-468.
Langerbeins P, Eichhorst B. Immune dysfunction in patients with chronic lymphocytic leukemia and challenges during COVID-19 pandemic. Acta Haematol 2021; 144: 508-518.
Manusow D, Weinerman BH. Subsequent neoplasia in chronic lymphocytic leukemia. JAMA 1975; 232: 267-269.
Tsimberidou AM, Wen S, McLaughlin P, O'Brien S, Wierda WG, Lerner S et al. Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma. J Clin Oncol 2009; 27: 904-910.
Benjamini O, Jain P, Trinh L, Qiao W, Strom SS, Lerner S et al. Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes. Leuk Lymphoma 2015; 56: 1643-1650.
Ishdorj G, Beiggi S, Nugent Z, Streu E, Banerji V, Dhaliwal D et al. Risk factors for skin cancer and solid tumors in newly diagnosed patients with chronic lymphocytic leukemia and the impact of skin surveillance on survival. Leuk Lymphoma 2019; 60: 3204-3213.
Keating MJ, O'Brien S, Lerner S, Koller C, Beran M, Robertson LE et al. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 1998; 92: 1165-1171.
da Cunha-Bang C, Rostgaard K, Andersen MA, Rotbain EC, Grønbaek K, Frederiksen H et al. Risk of new malignancies among patients with CLL treated with chemotherapy: results of a Danish population-based study. Br J Haematol 2021; 193: 339-345.
Shen Y, Coyle L, Kerridge I, Stevenson W, Arthur C, McKinlay N et al. Second primary malignancies in chronic lymphocytic leukaemia: skin, solid organ, haematological and Richter's syndrome. eJHaem 2022; 3: 129-138.
Mulcahy A, Mulligan SP, Shumack SP. Recommendations for skin cancer monitoring for patients with chronic lymphocytic leukemia. Leuk Lymphoma 2018; 59: 578-582.
Kovacs G, Robrecht S, Fink AM, Bahlo J, Cramer P, von Tresckow J et al. Minimal residual disease assessment improves prediction of outcome in patients with chronic lymphocytic leukemia (CLL) who achieve partial response: comprehensive analysis of two phase III studies of the German CLL study group. J Clin Oncol 2016; 34: 3758-3765.
Böttcher S, Ritgen M, Fischer K, Stilgenbauer S, Busch RM, Fingerle-Rowson G et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol 2012; 30: 980-988.
Rawstron AC, Kennedy B, Evans PAS, Davies FE, Richards SJ, Haynes AP et al. Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood 2001; 98: 29-35.
Wierda WG, Rawstron A, Cymbalista F, Badoux X, Rossi D, Brown JR et al. Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations. Leukemia 2021; 35: 3059-3072.
Rawstron AC, Fazi C, Agathangelidis A, Villamor N, Letestu R, Nomdedeu J et al. A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study. Leukemia 2016; 30: 929-936.
AIHW. Indigenous Life Expectancy and Deaths [Internet]. Available from URL: https://www.aihw.gov.au/reports/australias-health/indigenous-life-expectancy-and-deaths
Ministry of Health. Cancer: New Registrations and Deaths 2013. Wellington: Ministry of Health; 2016.